NCT04015687

A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults

A Phase 1, Open-label Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Agios Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to examine the effect of multiple doses of AG-881 on the pharmacokinetics (PK) of a single dose of lamotrigine in healthy adults.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	AG-881	Supplied as uncoated tablets.
DRUG	Lamotrigine	Supplied as tablets of LAMICTAL® or generic equivalent.

Timeline

• Start date: 2019-07-15
• Primary completion: 2019-10-09
• Completion: 2019-10-09
• First posted: 2019-07-11
• Last updated: 2019-10-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study